Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda (NECS)
Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda
Sponsor: Epicentre
Terminated
Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was taken to terminate recruitment in March 2003.
A PHASE2/PHASE3 clinical study on Trypanosomiasis, African, this trial is terminated or withdrawn. The trial is conducted by Epicentre and has accumulated 11 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
-
May 2018 — Nov 2020 [monthly]
Terminated PHASE2_PHASE3
-
Mar 2018 — May 2018 [monthly]
Terminated PHASE2_PHASE3
-
Aug 2017 — Mar 2018 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Jun 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
Oct 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Epicentre
- Médecins Sans Frontières, France
For direct contact, visit the study record on ClinicalTrials.gov .